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Abstract
Strong laboratory services and systems are critical for delivering timely and quality health services 
that are vital to reduce patient attrition in the HIV treatment and prevention cascade. However, 
challenges exist in ensuring effective laboratory health systems strengthening and linkages. In 
particular, linkages and referrals between laboratory testing and other services need to be 
considered in the context of an integrated health system that includes prevention, treatment, and 
strategic information. Key components of laboratory health systems that are essential for effective 
linkages include an adequate workforce, appropriate point-of-care (POC) technology, available 
financing, supply chain management systems, and quality systems improvement, including 
accreditation. In this review, we highlight weaknesses of and gaps between laboratory testing and 
other program services. We propose a model for strengthening these systems to ensure effective 
linkages of laboratory services for improved access and retention in care of HIV/AIDS patients, 
particularly in low- and middle-income countries.
Introduction
Over the past decade, low- and middle-income countries, in collaboration with international 
partners, have made tremendous progress towards improving access to diagnosis, treatment, 
and prevention of HIV/AIDS. New HIV infections, morbidity, and mortality have decreased, 
and the proportions of people who know their HIV status and are enrolled into antiretroviral 
treatment (ART) programs have increased significantly.1–3 Sustaining and maximizing these 
gains is critical but there are many challenges. While ART efforts are being scaled up 
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globally, patient attrition remains high between HIV diagnosis, enrollment, and retention in 
care.4–6
Laboratory testing plays a central role in this cascade of HIV treatment and prevention 
services, defined as series of stages from HIV diagnosis, linkage to, and retention in care, 
commencement of antiretroviral treatment (ART), adherence, and viral load suppression that 
translates to reduced risk of death and HIV transmission.7,8 Testing often stands at the 
thresholds of different stages of the cascade: diagnosing infection, determining eligibility for 
ART and/or prophylaxis, determining the efficacy and safety of treatment, and facilitating 
clinical decision-making (Fig. 1). However, it is often at these thresholds that patients are 
lost to follow-up. For example, a recent systemic review of the proportion of adult patient 
retention between any two points within the HIV treatment cascade showed that 59%, 46%, 
and 68% of patients were retained from HIV testing to receipt of CD4 count results, staging 
to ART eligibility, and from ART eligibility to ART initiation, respectively.5 Weaknesses in 
linkages between testing and follow-up clinical care are a major cause for low retention, 
compromise treatment, and prevention efforts. Strategies are needed to address these 
weaknesses and to ensure effective linkages and referrals to other services after laboratory 
testing within the cascade pathway. Models that improve linkages of services within an 
integrated health system are successful.9 In this article we review current gaps, discuss ways 
to address them, and highlight the central role of laboratory services and systems and their 
linkages and referrals to other components of the HIV treatment and preventio cascade.
Methodological Approach
Electronic sources that included PubMed, Cochrane library, MEDLINE, AIDSONLINE, and 
conference abstracts were searched to obtain current information on this subject and to 
ensure that similar reviews have not been published elsewhere. The search themes include 
laboratory health systems strengthening in resource-limited settings, linkages, and referrals 
between the laboratory and HIV treatment and prevention cascades, and attrition and loss to 
follow up. The initial approach involved reviewing abstracts and titles of articles. Articles 
with information relevant to the search themes were selected for detailed review. Full text of 
pertinent references that are cited in the original articles were also searched and reviewed to 
confirm validity and consistency of the information stated. Some of the information and 
references are also included in the current review article. Full text and abstract with bias or 
doubtful methodologies were excluded.
Results and Discussions
The write-up of the article was structured to ensure consistency of information flow and 
relevance to the title, starting with a proposed model to show the centrality of the laboratory 
in HIV treatment and prevention cascade and then a review of the literature and discussions 
to emphasize the need to strengthen linkages between the laboratory prevention, treatment, 
strategic information, and other health systems strengthening attributes that are associated 
with laboratory services and systems as outlined below. Detailed results and discussions are 
presented as follows:
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Need for Laboratory Services and Systems Integration, Linkages, and 
Referrals to Other Services
The World Health Organization (WHO) recommends strengthening integrated health 
systems as a way to leverage resources and to ensure access to affordable healthcare. Some 
examples are the integration of HIV/AIDS, tuberculosis, malaria, maternal and child health 
(MCH), and noncommunicable diseases (NCDs)10 and the integration of prevention-of-
mother-to-child-transmission (PMTCT) services into MCH systems.11 Successful 
integration of services requires effective linkage of one service system to another for an 
uninterrupted continuum of care. Referral processes within an integrated HIV/AIDS care 
continuum depend heavily on successful laboratory linkages.8 This is because the laboratory 
is centrally located or has a cross-cutting relationship with other services such as prevention, 
treatment, and surveillance, which are key attributes of the cascade. Hence, efforts should be 
put in place to ensure effective integration and strengthening of these linkages and referral 
services between the laboratory and other health services and systems within a treatment and 
prevention cascade.
Laboratory prevention linkages
HIV prevention is designed for intervention before exposure, at exposure, immediately after 
exposure, and for longer periods after exposure. Timely diagnosis of individuals and referral 
to treatment at any of these stages are dependent, at least in part, on the laboratory. The 
absence of HIV testing and counseling (HTC) services with linkages to laboratory capacity 
to support a diagnosis has been responsible for low rates of testing, low knowledge of HIV 
status, and poor design and implementation of HIV prevention strategies in certain settings. 
For example, earlier data from more than 10 sub-Saharan African countries indicate that 
more than 60% of people living with HIV (PLWH) do not know their HIV status.12 The 
most recent UNAIDS report2 indicates that more than 50% of people living with HIV 
worldwide do not know their HIV status. Additionally, studies from Uganda and Kenya have 
reported that more than 80–90% of PLWH do not know their partner’s HIV status.13,14 This 
could be due to several factors, including the fact that in some resource-limited settings the 
majority of HIV-infected persons either live in rural communities or they are unable to 
access HIV diagnostic services at the central laboratory level due to logistical challenges, 
stigma, and discrimination.15 To overcome this, strategies to encourage the uptake of point-
of-care (POC) HIV rapid testing and its effective integration and linkages to HTC services 
are necessary to ensure scale-up diagnostic and referral support services and systems within 
these countries.
Although studies have shown concordance between HIV testing conducted at a central 
laboratory compared to peripheral and community levels, including testing performed by 
trained nonlaboratory personnel, some HTC programs still choose to send positive HIV 
samples from combination community HIV rapid testing to the central laboratory for 
retesting and confirmation. This may impact program uptake and contribute to attrition and 
loss to follow-up care documented in some settings because some of the people tested do not 
return for their test results.1,5 Delays in filling such programmatic gaps will impact current 
efforts as timely knowledge of HIV serostatus through testing is critical for effective HIV 
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prevention and treatment support services. As these programs are established in the 
communities and rural settings, policy changes are needed. These include supporting task 
shifting that will allow trained nonlaboratory persons, including counselors, outreach 
workers, and nurses to be engaged in HIV rapid testing since the limited qualified laboratory 
staff will not be able to support the increased demand for more qualified testers.16 Ensuring 
the accuracy of HIV rapid test results is critical. All testers should be well trained with 
emphasis on practical hands-on and then certified for competency. Testers and sites should 
participate in external quality assurance or proficiency testing programs and the use of 
standard documentation to ensure quality of rapid testing. Community-based HIV rapid 
testing and immediate release of test results is necessary to decrease the number of patient 
loss to follow-up. This can only be achieved where there is improved laboratory-prevention 
linkage. There is evidence of reduction in HIV transmission behaviors among individuals 
and couples in settings where laboratory-prevention linkages have been strengthened.17
Another challenge encountered by the interface between laboratory services and prevention 
strategies is the lack of capacity for more sophisticated testing that is needed for the 
diagnosis of early or acute HIV infection. In HIV infection, viral load is usually very high 
during the acute or early phase of infection.18 Transmission rates during acute or early HIV 
infection are higher than in chronic infection.19 The treatment as prevention paradigm is 
based on the premise that high viral loads lead to increased likelihood of HIV 
transmission.20 Hence, strategies to identify infected persons early and to get them into 
treatment to reduce viral loads and prevent transmission will be very helpful. Unfortunately, 
routine serological assays for HIV diagnosis are limited by their sensitivity to detect HIV 
infection during the acute or early infection period because of the window period, or the 
time it takes for serological antibodies to develop.21 This may result in a missed diagnosis 
and lead to an increased risk of further transmission. To fill this gap, more sensitive 
diagnostic assays, including pooled HIV RNA screening, and other antigen tests should be 
used as follow-up tests, particularly for discordant serological samples and for samples from 
people at high risk for HIV infection whose results are negative with serological assays. 
Early HIV diagnosis among infants to determine their status and to institute strategies to 
prevent infection among those diagnosed HIV negative is an important prevention approach. 
Serological testing is not accurate in diagnosing HIV infection among newborn infants since 
passive transfer of maternal antibodies can persist for as long as 18 months.22 Molecular 
testing such as DNA PCR would be required for early infant diagnosis (EID) to support 
PMTCT programs. However, advanced molecular testing for EID and early or acute adult 
HIV infection, including pooled HIV RNA, may not be available at the peripheral or 
community levels of the national health systems in most developing countries.23 To improve 
access to high technology and more sensitive diagnostic assays to support HIV prevention 
among infants and adults, it is recommended that laboratory referral services and laboratory 
networks for these diagnostic platforms should be strengthened and linked to HIV 
prevention services. Ultimately, POC tests are urgently needed to expand the capacity for 
accurate diagnostics in a decentralized manner, but until that time reference laboratories will 
continue to have a critical role.
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Laboratory treatment and care linkages
The 2011 landmark HIV Prevention Trials Network 052 study showed conclusively that 
treatment reduced HIV viral load and decreases the risk of HIV transmission.20 Several 
recommendations, including the WHO clinical staging guidelines12 and various health 
economics cost-benefit theories,24 have highlighted the benefits of different treatment 
options to include initiation of ART at CD4 cell counts > 350 and > 500 cells/mm3, as well 
as Option B+ strategies25 that does not require measurement of CD4 cells to initiate 
treatment.26 These recommendations show that all newly diagnosed patients should be 
placed on ART as soon as possible to obtain optimal benefits. A study from South Africa 
showed that early HIV diagnosis and early ART reduced early infant mortality by 76% and 
HIV progression by 75%.27 The laboratory has a central role in HIV treatment monitoring 
(e.g., staging and enrollment into ART, effectiveness of treatment, toxicity, and drug 
resistance testing). Despite this, poor access to laboratory services is still negatively 
impacting HIV treatment program uptake. For example, in Malawi, data from more than 
8000 mother–infant pairs showed that infected infants have at least a five to eight times 
higher rate of death compared to uninfected children because of lack of a laboratory facility 
for HIV DNA PCR testing that is needed to identify infected children who could benefit 
from ARV treatment.28 A systemic review article on patient retention in an ART program in 
sub-Saharan Africa showed that less than 59% of patients either received CD4 results or 
were staged after diagnosis; and 75% of these patients were retained in care 1 year after 
initiation of ART.29 Also, a joint WHO/UNAIDS/UNICEF30 publication stated that only 
24% of HIV-positive pregnant women in low- and middle-income countries received CD4 
test results. Finally, increased access to HIV viral load testing has also become a critical and 
limiting issue in low- and middle-income countries due to the expansion of ART.1 Weak or 
poor access to laboratory testing services to support HIV treatment undoubtedly contributes 
to these challenges. These services need to be restructured and strengthened to improve 
treatment program uptake and to reduce the high patient attrition rate. For example, in 
Mozambique, after introducing point of careCD4 for same day results, the proportion of 
patients lost to follow-up before completion of CD4 staging dropped from 57% to 21%.3 A 
holistic approach to improving access to various laboratory services to support HIV 
treatment is necessary.
Laboratory strategic information linkages
Capturing patient data to monitor and ensure retention in care is an important component of 
the HIV treatment and prevention cascade. Key aspects of the cascade pathway depend on 
generation, tracking, analysis, and use of laboratory data. Some studies have reported 
substantial loss of patients at several steps in the cascade due to poor capturing and tracking 
of laboratory data.6,32 The lack of functional health information systems (HIS) and 
laboratory information systems (LIS) to track patients between different services has 
partially contributed to this challenge. LIS are needed to capture and report all testing data to 
the appropriate sections of the cascade and to the national central system by interfacing with 
HIS for wider access and coverage for policy decision making. Attrition at different steps of 
the continuum of care due to poor data capturing tools has been responsible for overall low 
levels of viral load suppression in a large population of PLWH.7 There have also been 
documented cases of mismatched HIV test results or the inability of testing services to 
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correctly track and deliver HIV test results because of poor or weak laboratory data 
collection systems.5 Bridging gaps and establishing linkages between the laboratory services 
and strategic information systems will be necessary to attain and sustain a positive HIV 
prevention and treatment impact. For example, in Uganda, incorporation of electronic 
records into clinical care led to a 30% reduction in missed visits compared to when these 
records were not incorporated.33 Setting up surveillance systems to capture laboratory data 
for analysis and decision making are necessary to refine and implement new strategies to 
improve access and utilization of HIV treatment and prevention services.
Health system strengthening attributes to improve laboratory services
Health systems strengthening (HSS) include attributes that ensure and guide a country’s 
ability to deliver quality health for the well-being of its population.34 There are key 
laboratory attributes that should be strengthened as components of an integrated health 
system to ensure that they are effectively linked to other services for maximum program 
impact.
Laboratory institutions and capacity strengthening—A lack of an adequately 
trained workforce has partly been responsible for some of the laboratory health systems 
challenges in developing countries.35 Part of this has been attributed to the lack of training 
institutions with a curriculum tailored to the needs of the laboratory and to a high attrition 
rate of already trained staff.36 Institutional capacity and training curriculum need to be 
reviewed, strengthened, and coordinated with strategies to retain staff. Also, strengthening 
laboratory services and systems, and developing and utilizing evidence-based user-friendly 
tools to improve quality systems, plus accreditation of laboratories as benchmarks for 
laboratory competence, are important. This will ensure a cadre of qualified laboratory staff 
and improved quality systems necessary to release test results in support of HIV treatment 
and prevention programs. Furthermore, appropriate human resources for health should be 
addressed. While task shifting has been used to fill certain gaps in health workforce cadre, 
efforts at seeking proportional or balance workforce to workload should be pursued.
Health systems financing—Health systems financing, negotiating reduced cost of 
laboratory commodities including procurement of equipment (servicing and maintenance 
contracts) and reagents, and building robust linkages through public—private partnerships 
with suppliers should also be targeted as an approach toward ensuring access to affordable 
testing.37 Data presented in this review highlight weak or poor access to laboratory services, 
partly associated with high cost or nonavailability of laboratory testing services. This 
negatively impacts treatment and prevention efforts. Cost reduction for laboratory equipment 
and reagents through health systems financing will ultimately reduce the cost per test and 
will improve access to HIV diagnostic services, enrollment into care and treatment, and 
reduction in patient attrition within the cascade. Furthermore, availability of funds through 
health systems financing will improve the supply chain management system and ensure 
rapid procurement and delivery of laboratory commodities. This will reduce turnaround time 
for testing and delivery of results, resulting in improved endpoint service delivery within the 
HIV treatment and prevention cascade.
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Point of care technology—Difficulties in accessing laboratory services for CD4 cell 
counts, HIV viral load, and DNA PCR in resource poor settings have hampered the 
effectiveness of PMTCT programs and other adult HIV diagnostic and treatment 
services.1,30 This has partly been attributed to the sophistication and cost of these 
technologies since they are not affordable in resource-constrained countries. The impact of 
simple, cheap, and affordable POC technologies in program expansion has been 
demonstrated in certain settings. For example, where there was prompt access to POC HIV 
rapid testing and CD4 cell counts, there was a tremendous improvement in the proportion of 
patients who were diagnosed, staged, and referred into care.1,31,38 Despite the benefits of 
POC technologies, they are not widely available for use in most countries because some of 
the technologies are still in the developmental stages. Moreover, in instances where POC 
technology is available, regulatory and bureaucratic issues have delayed their uptake. 
Developing appropriate policies and guidelines for POC technologies in sub-Saharan Africa 
will ensure that these beneficial technologies are rapidly rolled out for increased access. As 
POC technologies become available, they should be integrated and linked to treatment and 
prevention services to reduce gaps that lead to attrition of patients within the cascade 
pathway.
Operational Research Monitoring and Evaluation
As the entire health system is revisited to address new opportunities and challenges, 
monitoring and evaluation of any proposed models or structures is needed. As programs are 
expanded, both process and impact evaluations should be conducted to identify and correct 
any implementation gaps. Two possible indicators for measuring positive impact of HIV 
prevention and treatment cascade are reductions in HIV incidence and a corresponding 
increase in the number of people placed on ART. Suitable laboratory incidence assays are 
needed to measure HIV incidence. The treatment cascade contains different laboratory 
endpoints such as number of people diagnosed and linked to care, and the number of people 
retained in care measured through evidence of early infant and adult HIV diagnosis, CD4, 
and viral load test results. Targets should be set and indicators for these variables developed 
and measured to determine successes and challenges at various levels or stages of the 
treatment cascade. Implementing scientific research toward achieving these targets is highly 
encouraged. Using existing laboratory data for program impact evaluation as a quick means 
for developing policies to improve performance is recommended as a good start.
Conclusions
Collaborations between international and local partners and governments in low- and 
middle-income countries through evidence-based scientific research and directly funded 
interventions have led to tremendous improvements in HIV prevention and treatment efforts. 
The laboratory has a central role in all stages of the HIV treatment and prevention cascade 
pathway. Despite this, laboratory health systems remain weak and are poorly linked with 
other services within the continuum of care in low- and middle-income countries. Because 
of these gaps, it is difficult to realize HIV prevention and treatment benefits at the individual 
and population level within these countries. To overcome this, laboratory services and 
systems need to be strengthened to improve HIV treatment and prevention program uptake. 
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Ensuring linkages and referrals between the laboratory services and other services within an 
integrated health system is also needed to improve access to diagnosis, clinical monitoring, 
and to reduce attrition and lost to follow-up of HIV/AIDS patients on ART.
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Different stages of the HIV Treatment and Prevention Cascade. It starts from HIV diagnosis 
to CD4 measurement for clinical staging and determination of eligibility for ART. This is 
followed by monitoring for efficacy and safety of treatment through measurement of 
chemistry, hematology, and CD4 parameters, and opportunistic infections testing. The final 
stage involves measurement of viral load to determine outcome of treatment and follow up 
HIV drug resistance testing for patients failing therapy.
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